RESUMEN
The aim of this study was to evaluate the medium term effects of the selective alpha1-adrenenergic- blocker terazocin on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally for 30 days. The daily dose was 1 mg for the first 7 days, 2 mg for the next 7 days and 5 mg for the remaining period of this clinical trial. At the end of this clinical trial, plasma ANP levels increased by 16.40% despite the drop in blood pressure while left atrial and ventricular diameters remained unchanged. These findings indicate that the increase of ANP plasma levels is not the result of a mechanical load on the left cardiac chambers but the result of a pharmacological action. These observations also indicate that terazocin exerts part of its antihypertensive action by increasing ANP plasma levels.
Asunto(s)
Factor Natriurético Atrial/sangre , Hipertensión/sangre , Hipertensión/tratamiento farmacológico , Prazosina/análogos & derivados , Prazosina/uso terapéutico , Adulto , Anciano , Antihipertensivos/uso terapéutico , Humanos , Modelos Lineales , Masculino , Persona de Mediana EdadRESUMEN
Pyeloureteritis cystica is a rare situation of the renal pelvis and ureters, characterized by cystical formations of the epithelium. The etiology is unknown and there is no specific treatment. It is usually diagnosed accidently during imaging of the upper urinary tract for different reasons. We present a case of pyeloureteritis cystica.
RESUMEN
Intracavernous PO2 (mm Hg) was measured during flaccidity in 5 psychogenic impotent patients (control), in 9 patients with venous leak and in 10 patients with arterial disease. No significant difference was observed in the mean PO2 value between the control group 36.2 +/- 5.8 and patients with venous leak 35.6 +/- 6.9 or with arterial disease 34.1 +/- 6.5 at flaccidity. Ten minutes after injection of Prostaglandin E1 (PGE1), the mean value of cavernous PO2 in the control group 83.8 +/- 6.8 was significantly different (p < 0.01) from that in the venous group 67.8 +/- 8.2 and the arterial group 57.8 +/- 10.7 (p < 0.01). Using the computerized analysis and the immunohistochemical staining actin anti-actin, the mean percentage of cavernous smooth fibers was 43.3 +/- 3.6, 34.1 +/- 4.6, and 29.3 +/- 3.4 in the three groups of patients respectively. At flaccidity, the higher the PO2 value, the higher the percentage of cavernous smooth muscle fibers was detected (p < 0.05). A high correlation was observed between the increase in PO2 value after injection of PGE1 and the increase in cavernous smooth muscle content. On the other hand, the mean value of penile brachial index in the psychogenic 0.87 +/- 0.07 was significant different (p < 0.01) from the venogenic group 0.68 +/- 0.06 and the arteriogenic group 0.64 +/- 0.09 (p < 0.01). Similarly, a high correlation was detected between the increase in penile brachial index ratio and the increase in cavernous smooth muscle content. A decrease in the percentage of the intracavernous smooth muscle fibers could be explained by the low oxygen tension at flaccidity and therefore could be responsible for insufficient rigidity during erection.